Latest Safety Warning For Novartis's Gilenya Won't Hurt Sales
This article was originally published in Scrip
Executive Summary
A confirmed case of the rare, serious brain infection progressive multifocal leukoencephalopathy (PML) linked to Novartis' blockbuster oral multiple sclerosis drug Gilenya (fingolimod), along with a previously reported probable case of PML, have prompted the US FDA to issue a safety warning.